Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Growth Evolved From 2024 To 2025, And What’s Ahead?
The market size for chemotherapy-induced nausea and vomiting (CINV) has experienced substantial expansion in the past years. The market value is expected to rise from $2.92 billion in 2024 to $3.13 billion in 2025, with a compound annual growth rate (CAGR) of 7.4%. The surge in the historic timeframe can be attributed to an increase in chemotherapy usage, heightened antiemetic agents, clinical guideline advancements, and patient advocacy.
The market for chemotherapy-induced nausea and vomiting (CINV) is projected to experience significant growth in the coming years, reaching $4.19 billion in 2029 with a compound annual growth rate (CAGR) of 7.5%. The expected growth within the forecast period can be connected to the development of personalized medicine, improvements in antiemetic treatments, the rise in telehealth and remote monitoring, as well as health equity initiatives. The forecast period also signals key trends such as the increased use of combination antiemetic therapies, a rise in supportive care services, wider use of digital health tools, and an emphasis on survivorship care.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp
What Are the Core Growth Drivers Propelling the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Forward?
The rise in cancer occurrence is predicted to fuel the expansion of the chemotherapy-induced nausea and vomiting (CINV) market. Cancer develops when certain cells in the body grow out of control and invade other areas of the body. As the number of cancer patients increases, so does the urgency to create more targeted and efficient anti-emetic treatments to alleviate CINV, an unsettling side effect of chemotherapy. This intensified interest in managing CINV has led to progress in understanding its basic causes and the development of new treatments. For example, the American Cancer Society (ACS), a US-based volunteer health organization dedicated to eliminating cancer, anticipates there will be 1.9 million new cancer cases (around 5,370 cases per day) and 609,820 cancer-related deaths (approximately 1,670 deaths per day) in the United States in January 2023. As such, the rising prevalence of cancer is set to boost the chemotherapy-induced nausea and vomiting (CINV) market.
What Segment Types Define the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Structure?
The chemotherapy-induced nausea and vomiting (cinv)market covered in this report is segmented –
1) By Form: Injectables; Oral; Transdermal Patches
2) By Drug Class: 5-HT3 Receptor Antagonists; Neurokinin-1 Receptor Antagonists; Corticosteroids; Cannabinoids; Other Drug Class
3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC); Moderately Emetogenic Chemotherapy (MEC); Low Emetogenic Chemotherapy (LEC)
4) By Distribution Channel: CINV Hospitals; Cancer Research Institute; Retail Pharmacies; Online Pharmacies; Drug Stores
5) By Application: Gynecology; Urology; Gastrointestinal Surgery; Other Applications
Subsegments:
1) By Injectables: Intravenous (IV) Solutions; Intramuscular (IM) Injections
2) By Oral: Tablets; Capsules; Liquid Formulations
3) By Transdermal Patches: Fentanyl Patches; Scopolamine Patches
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13031&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Which Emerging Trends that Are Influencing theChemotherapy-Induced Nausea and Vomiting (CINV) Industry Evolution?
Leading firms in the chemotherapy-induced nausea and vomiting (CINV) sector have been focusing on new innovative products, like fixed intravenous antiemetic, to strengthen their market position. Such fixed intravenous antiemetics refer to a pre-determined medication dosage given through IV to manage nausea and vomiting, typically in post-surgery and chemotherapy situations. For instance, in January 2023, Glenmark Pharmaceuticals Limited, an Indian pharmaceutical, generics, and over-the-counter (OTC) goods manufacturer, brought the first fixed intravenous antiemetic combination, AKYNZEO I.V., to India. This product is specifically designed to combat CINV and includes a blend of netupitant and palonosetron, aiming to handle both the immediate and delayed phases of nausea and vomiting. It provides convenience of a single dose, improved total response rates and enhances the quality of life for cancer patients. According to clinical research, it has shown to be particularly advantageous for those undergoing highly emetogenic chemotherapy.
View the full report here:
What Is the Definition of the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
Chemotherapy-induced nausea and vomiting (CINV) is a condition that causes nausea and vomiting sensation, which can develop due to chemotherapy treatment. It is a prevalent side-effect affecting many cancer patients, affecting their quality of life and treatment results. CINV can be managed and treated through medications and lifestyle changes.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13031
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model